Literature DB >> 22825724

Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH.

Matthieu Talagas1, Pascale Marcorelles, Arnaud Uguen, Sylvia Redon, Isabelle Quintin-Roué, Sebastian Costa, Claude Férec, Frédéric Morel, Phong Dam Hieu, Marc De Braekeleer.   

Abstract

Oligodendroglial tumors (ODTs) are primary tumors of the central nervous system that show recurrent codeletion of whole chromosome arms 1p and 19q. Non-1p/19q-deleted high-grade ODTs can present other genetic aberrations, CDKN2A deletion (9p21.3), EGFR amplification (7p11.2) and/or chromosome 10 loss, which are associated with a poor prognosis. The identification of these abnormalities allowed drafting a histo-molecular classification. The aim of this study was to precisely identify, using array CGH, the genomic hallmarks of these tumors, particularly those that are not deleted on 1p/19q. We studied 14 formalin-fixed paraffin-embedded high-grade ODTs using pangenomic oligonucleotide array CGH with an average resolution of 22.3 kb. The 1p/19q codeletion was found in five anaplastic oligodendrogliomas. The three genomic aberrations carrying a poor prognosis were found, most often associated, in five out of nine tumors not deleted on 1p/19q. In addition, four recurrent copy number alterations, involving genes that participate to cell growth and cycle, were found to be strongly associated in five tumors not deleted on 1p/19q: gain or amplification at 1q32.1 (MDM4, PIK3C2B genes), 12q14.1 (CDK4 gene), 12q14.3-q15 (MDM2 gene) and homozygous deletion at 22q13.1 (APOBEC3B gene). MDM2, MDM4, CDK4 and PIK3C2B are known for potentially being amplified or overexpressed in high-grade gliomas. However, the involvement of APOBEC3B, coding for mRNA edition enzyme, is described here for the first time. Our results show a strong association between these four alterations. Therefore, this can open a perspective for a novel subgroup in high-grade ODTs not deleted on 1p/19q.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825724     DOI: 10.1007/s11060-012-0909-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  Isolation and characterization of human orthologs of yeast CCR4-NOT complex subunits.

Authors:  T K Albert; M Lemaire; N L van Berkum; R Gentz; M A Collart; H T Timmers
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

3.  Small CTD phosphatases function in silencing neuronal gene expression.

Authors:  Michele Yeo; Soo-Kyung Lee; Bora Lee; Esmeralda C Ruiz; Samuel L Pfaff; Gordon N Gill
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

Review 4.  [Advances in adults' gliomas biology, imaging and treatment].

Authors:  F Ducray; G Dutertre; D Ricard; E Gontier; A Idbaih; C Massard
Journal:  Bull Cancer       Date:  2010-01       Impact factor: 1.276

5.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

6.  Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

Authors:  Brian P Doehle; Alexandra Schäfer; Bryan R Cullen
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

Review 7.  Molecular pathogenesis of oligodendroglial tumors.

Authors:  Judith W M Jeuken; Andreas von Deimling; Pieter Wesseling
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

8.  High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

Authors:  Markus Bredel; Claudia Bredel; Dejan Juric; Griffith R Harsh; Hannes Vogel; Lawrence D Recht; Branimir I Sikic
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

9.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

10.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.

Authors:  H Matsushime; M E Ewen; D K Strom; J Y Kato; S K Hanks; M F Roussel; C J Sherr
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

View more
  5 in total

1.  Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas.

Authors:  David Nauen; Lisa Haley; Ming-Tseh Lin; Arie Perry; Caterina Giannini; Peter C Burger; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2015-08-14       Impact factor: 6.508

2.  APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.

Authors:  Dennis Xuan; Guoliang Li; Qiuyin Cai; Sandra Deming-Halverson; Martha J Shrubsole; Xiao-Ou Shu; Mark C Kelley; Wei Zheng; Jirong Long
Journal:  Carcinogenesis       Date:  2013-05-28       Impact factor: 4.944

3.  Chromosomal Aberrations in Canine Gliomas Define Candidate Genes and Common Pathways in Dogs and Humans.

Authors:  Peter J Dickinson; Dan York; Robert J Higgins; Richard A LeCouteur; Nikhil Joshi; Danika Bannasch
Journal:  J Neuropathol Exp Neurol       Date:  2016-05-31       Impact factor: 3.685

4.  Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.

Authors:  Saeko Hayashi; Hikaru Sasaki; Tokuhiro Kimura; Takayuki Abe; Takumi Nakamura; Yohei Kitamura; Tomoru Miwa; Kaori Kameyama; Yuichi Hirose; Kazunari Yoshida
Journal:  Oncotarget       Date:  2015-06-30

5.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.

Authors:  Arnaud Uguen; Matthieu Talagas; Sebastian Costa; Sandrine Duigou; Stéphanie Bouvier; Marc De Braekeleer; Pascale Marcorelles
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.